HomePipelinePNB-001Type 2 Diabetes

PNB-001

Type 2 Diabetes

PNB-001 for the Treatment of Type 2 Diabetes

Molecule
PNB-001
Development status
Phase 2 submission
Therapeutic area
Metabolic Diseases
Biological action
CCK-mediated blood glucose reduction; restoration of pancreatic cells
Therapeutic target
Incretin, reduction of blood glucose levels

Stage of development

  • PNB-001

    Type 2 DiabetesCCK-mediated blood glucose reduction; restoration of pancreatic cells

Graph of the stage of development of PNB-001 in Type 2 Diabetes. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Background about target

In line with the increase in Obesity T2 Diabetes is rising and T1 Diabetes is associated with immune dysregulation and immune attack on the beta cell with the known loss of insulin production. PNB-001 is developed from immune mediated Inflammatory Diseases and the term incretin was first used in immunology and know it is an agent to release insulin.

CCK was known as incretin, most accurately as non-classical incretin in addition to GIP (gastrin inhibiting peptide, = later termed glucose dependent insulinotropic polypeptide) and GLP1. GIP was neglected as Diabetes target, because GIP was impaired in diabetic patients. Now, there is an enormous celebration of the GLP1-target in Diabetes and in particular Obesity. The CCK target was neglected as CCK8 or CCK8s was known and only a new CCK derivative could be patented.

After the GLP1 peptide success in stabilizing the peptide’s plasma half-life, Novo in Denmark launched a programme with a peptide based CCK drug, but the drug was of only CCK A agonistic activity and this in principal can trigger Pancreatitis.

PNB-001 is a CCK A agonist and CCK B antagonist and this is reducing lipase in patients as seen in phase 1 SAD. The dual acting mechanism was found a key feature in immune inflammation and here in the treatment of Diabetes, too.

Introduction of treatment options

The new developments towards peptide hormone targets, potently releasing insulin, are all modified stabilized GLP1 agonists. The programmes were in response to the discovery of the exceptionally good anti-diabetic properties of native GLP1 in a clinical trial.

Novo’s first GLP1 agonist generation drug was liraglutide, which was improved in a second generation agents (only mono acting GLP1 agonist), termed semaglutide allowing 1 weekly injection. Boeringer Ingelheim developed a glucagon / GLP1 agonist, Sanofil a fixed insulin GLP1 fixed combination. Now in a nutshell GLP1 agonists were replaced by dual acting GLP1 and GIP agonists, injection first and then attempts to launch orally active drugs as for semaglutide for example.

Lilly is the current leader with retratutide and lotiglipron by injection and triple action. Previously tirzepatide, a dual acting GLP1/GIP agonist, was launched very successfully under the name Mounjaro by injection. Pfizer developed the first orally available GLP1/GIP agonist dassugliprom, which is currently in phase 3. Sun pharma is launching ureglutide by injection and only mono GLP-1action with big claims.

Preclinical studies:

PNB-001 is developed as novel chemical entity to address the therapeutic area of immune mediated Inflammatory Diseases. It completed a phase 2 clinical trial in Covid Lung Inflammation, progressed to phase 3. Ongoing is the phase 2 clinical trial in IBD. The antidiabetic effect was first clinically identified in Covid patients and CCK is described in the literature as non-classical integrin to release insulin for decades.

The antidiabetic properties of the agent were initially performed in heathy rats using the oral glucose tolerance test. The modified STZ/NA assay in rats was performed to evaluate the antidiabetic glucose lowering effects in diabetic animals. Glucagon and insulin was analysed. In adddtion to anti-diabetic properties, the effects on inflammatory diabetic nephrophathy were investigated.

A bell shaped dose response curve was determined for the antidiabetic effect with a maximum at 3mg/kg and a linear range from 0.3-1-2mg/kg. At higher doses, the antidiabetic effect is reduced for the right part of the bell shaped curve. The anti-inflammatory effect is in the 10-20 mg/kg range.

In the OGTT, PNB-001 was found highly potent in lowering blood glucose and the duration of this effect is >10h, allowing 2x dosing intervals.

The efficacy is identified in healthy and diabetic animals. Under pathological conditions the dose required is slightly higher than physiological conditions.

From 28 day data analysis of the insulin and glucagon baseline, it was found, that the pancreas is restored to a nearly healthy level and therefore, an organ repair is proposed. PNB-001 acted as antidiabetic glucose lowering agent by releasing insulin. In diabetic animals the insulin release was increased >400%.

PNB-001 acted as non-classical incretin, a first small molecule non-peptidal incretin.

Preclinical development studies:

PNB-001 had a half-life of 9 hrs and had a relatively low bioavailability. PNB-001 was evaluated in various ADME studies, including cytochrome P450 enzyme inhibition, plasma protein binding, and CaCo2 permeability. PNB-001 did not inhibit Cyp3A4, Cyp2C9, and Cyp1A2 up to 10 µM and Cyp2C19 until 3 µM. With 97% of PNB-001 bound to rat and human plasma, the amount of free unbound PNB-001 is comparable to some of the marketed drugs. CaCo2 permeability studies indicated that PNB-001 has high permeability and is not effluxed in the B>A direction.

Regulatory toxicology and safety pharmacology studies (acute toxicity studies in rats and mice, 7 day dose range finding studies in rats and dogs, 28 days toxicology studies in rats and dogs, PK studies in rats and dogs, safety pharmacology studies (cardiac, renal, respiratory, and neuro), chromosomal aberration and mutagenesis studies) conducted with PNB-001 under GLP environment and in accordance with ICH guidelines demonstrate extremely high levels of safety and tolerability.

Synthetic chemistry:

PNB-001 synthetic schema has been established both in non-GMP and in GMP conditions. Moreover, synthetic chemistry efforts are optimized to synthesize PNB-001 one a multi kg scale.

About PNB-001

Clinical · Phase 1 and Phase 2 completed

The front runner of the portfolio.
Developed from immune-mediated
Inflammatory research, PNB-001 is in Phase 3 for Covid-19 and has completed Phase 2 in Ulcerative Colitis & Crohn's Disease

PNB-001 full profile

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.